Answers are grounded in this paper and cite their sources.
Nanoparticles of a mesoporous iron(iii) trimesate MIL-100 nanocarrier encapsulating high amounts of the challenging antineoplastic busulfan were administered to rats and compared with the commercial Busilvex®. Large differences in serum concentration of both busulfan and trimesate revealed the great impact of drug encapsulation both on the drug and on nanoparticle pharmacokinetics during the first 24 h of administration.
No takes yet. Share an insight, caveat, or question.
Simón‐Yarza et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: